7 Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H et al. DURATION-1: exenatide once weekly produces sustained glycemiccontrol and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255–1261. 8 Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)- amide an antagonist at the glucagon-like peptide 1-(7-36)-amidereceptor of insulin-secreting b-cells. J Biol Chem 1993; 268: 19650– 19655. 9 Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro .Metab Clin Exp 2001; 50: 583–589. 10 Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JAet al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.Diabetes Care 2005; 28: 1547–1554. 11 Tu ST, Chang SJ, Chen JF, Tien KJ, Hsiao JY, Chen HC et al. Prevention of diabetic nephropathy by tight target control in an